To evaluate the everolimus potential to restore sensitivity to gefitinib and cetuximab in cancer cell lines resistant to these anti-EGFR drugs, we performed a soft agar assay on cells treated with doses of cetuximab or gefitinib ranging from 0.1 to 1 μg ml−1 and from 0.1 to 1 μM, respectively, in presence of everolimus 0.1 μM. This evidence concerns the gene EGFR and cancer.